Predictive ability of scores for bleeding risk in heart disease outpatients on warfarin in Brazil | PLOS ONE
Evaluation of Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in the Oncology Population Jessica Hedvat, PharmD PGY-1 Pharmacy. - ppt download
Long-Term Risk of Clinically Relevant Non-Major Bleeding During Extended Anticoagulation for Unprovoked Venous Thromboembolism: A Systematic Review and Meta-Analysis - ISTH Congress Abstracts
A Phase IV Study of Thromboembolic and Bleeding Events Following Hip and Knee Arthroplasty Using Oral Factor Xa Inhibitor - ScienceDirect
Clinical performance of bleeding risk scores for predicting major and clinically relevant non-major bleeding events in patients
Individual Benefits and Harms of Extended Anticoagulation in Patients with Venous Thromboembolism: The VTE-PREDICT Model - ISTH Congress Abstracts
Cost–utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer | CMAJ
Nephrology Journal Club on X: "T1h: Outcomes were defined accordingly with International Society on Thrombosis and Haemostasis @isth #NephJC https://t.co/b0tQMjYKbE" / X
PPT - DVT Prophylaxis in Orthopedic Patients PowerPoint Presentation, free download - ID:2670969
PPT - John H. Alexander, MD, MHSc Duke Clinical Research Institute, Durham, NC, USA Lars Wallentin, MD, PhD Uppsala Clinical R PowerPoint Presentation - ID:154927
MASTER DAPT | Terumo Interventional Systems
Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial
PACIFIC-AF: Low bleeding rates for asundexian in atrial fibrillation - Medical Conferences
Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial | Haematologica
Anthos' Blood Thinner Abelacimab Outperforms Rivals in Safety by 67% in AF Patients
Assessing Bleed Severity and Managing Major and Non-Major Bleeds | Download Scientific Diagram
MASTER-DAPT: “the MASTER of high-bleeding risk trials”
Risk of adverse outcomes after clinically relevant non-major bleeding | Download Scientific Diagram
Cancers | Free Full-Text | A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal,
CRNM - "Clinically Relevant Non-Major Bleeding" by AcronymsAndSlang.com
Rivaroxaban after Thrombolysis in Acute Iliofemoral Venous Thrombosis: A Randomized, Open-labeled, Multicenter Trial | Scientific Reports
Frontiers | Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy
Supplementary file 2. Primary and secondary outcomes
Comparison of clinical trial major and clinically relevant nonmajor... | Download Table
